Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
VSTM Stock Summary
Top 10 Correlated ETFs
VSTM
In the News
3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024
In the vast landscape of today's markets, artificial intelligence (AI) is reshaping investment strategies. Therefore, AI stock picks are as relevant as ever.
Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib
Rolling NDA submission of avutometinib + defactinib for the treatment of patients with low-grade serous ovarian cancer is expected in the 1st half of 2024, with possible commercialization in 2025. Results from two studies, RAMP-203 and RAMP-204, each using avutometinib with two different types of KRAS G12C inhibitors for the treatment of KRAS G12C NSCLC, expected mid-2024. The global non-small cell lung cancer market is expected to reach $38.8 billion by 2030; About 13% of NSCLC patients have the KRAS G12C mutation.
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.
3 Off-the-Beaten-Path Stocks Poised for Substantial Growth
As horror film fans know, there's safety in numbers but robust profitability may be more closer to the domain of uncommon stocks to buy for growth. Don't get me wrong – if you find yourself facing the market equivalent of a hockey-mask-wearing villain, you should probably consider the tried-and-true strength-in-numbers narrative.
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. To clarify, the ideas present tremendous risks.
3 Penny Stocks to Buy to Turn $1 into $100: November 2023
In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through penny stocks.
All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy
Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Verastem: Potential Accelerated Approval Filing In H1 2024
An application for Accelerated Approval of avutometinib + defactinib for low-grade serous ovarian cancer patients is expected in the first half of 2024. The ongoing RAMP-301 study is being done to keep avutometinib + defactinib for LGSC on the market or to convert Accelerated Approval to Full Approval. Company entered into a collaboration agreement with GenFleet Therapeutics to expand its pipeline and strengthen its position in the RAS driven cancer pathway space.
Verastem: Signs Of Life For A Beaten-Down Equity
Verastem is a biotechnology company focused on developing novel agents for solid tumors, with its main candidate being avutometinib. Avutometinib is being studied in various cancers, driven by RAS pathway activation, with promising early results in relapsed/refractory low-grade serous ovarian carcinoma. Verastem has sufficient cash to reach a new milestone in 2024 or early 2025, but more data is needed to determine if avutometinib is a viable solution in solid tumor oncology.
Verastem Oncology to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference; podium presentation on Tuesday, September 12, 2023 at 2:00 p.m. ET 2023 Cantor Global Healthcare Conference; fireside chat on Tuesday, September 26, 2023 at 9:55 a.m. ET A live webcast of the.
VSTM Financial details
VSTM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.81 | 6.93 | 0.14 | 0.16 | 0 | |
Net income per share | -27.22 | -5.3 | -5.58 | -4.58 | -3.96 | |
Operating cash flow per share | -22.29 | -2.62 | -3.68 | -3.95 | -3.92 | |
Free cash flow per share | -22.29 | -2.62 | -3.69 | -3.95 | -3.92 | |
Cash per share | 12.15 | 11.05 | 12.33 | 5.45 | 6.26 | |
Book value per share | 1.15 | 9.02 | 6.02 | 2.94 | 3.56 | |
Tangible book value per share | -2.07 | 9.02 | 6.02 | 2.94 | 3.56 | |
Share holders equity per share | 1.15 | 9.02 | 6.02 | 2.94 | 3.56 | |
Interest debt per share | 20.62 | 3 | 0.89 | 1.81 | 2.05 | |
Market cap | 99.93M | 326.59M | 357.53M | 77.46M | 179.52M | |
Enterprise value | 163.95M | 281.35M | 259.54M | 29.59M | 142.24M | |
P/E ratio | -0.59 | -4.82 | -4.41 | -1.05 | -2.05 | |
Price to sales ratio | 5.72 | 3.69 | 174.15 | 29.84 | 0 | |
POCF ratio | -0.72 | -9.75 | -6.68 | -1.22 | -2.08 | |
PFCF ratio | -0.72 | -9.74 | -6.66 | -1.22 | -2.08 | |
P/B Ratio | 13.93 | 2.83 | 4.08 | 1.63 | 2.29 | |
PTB ratio | 13.93 | 2.83 | 4.08 | 1.63 | 2.29 | |
EV to sales | 9.39 | 3.18 | 126.42 | 11.4 | 0 | |
Enterprise value over EBITDA | -1.3 | -5.91 | -4.24 | -0.41 | -1.55 | |
EV to operating cash flow | -1.18 | -8.4 | -4.85 | -0.46 | -1.65 | |
EV to free cash flow | -1.18 | -8.39 | -4.83 | -0.46 | -1.65 | |
Earnings yield | -1.69 | -0.21 | -0.23 | -0.95 | -0.49 | |
Free cash flow yield | -1.39 | -0.1 | -0.15 | -0.82 | -0.48 | |
Debt to equity | 14.99 | 0.2 | 0.03 | 0.57 | 0.52 | |
Debt to assets | 0.74 | 0.15 | 0.03 | 0.28 | 0.27 | |
Net debt to EBITDA | -0.51 | 0.95 | 1.6 | 0.67 | 0.41 | |
Current ratio | 2.84 | 8.48 | 5.69 | 4.29 | 5.45 | |
Interest coverage | -6.42 | -3.13 | -6.16 | -34.13 | -22.25 | |
Income quality | 0.93 | 0.49 | 0.75 | 0.86 | 0.99 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 2.62 | 0.47 | 19.17 | 19.48 | 0 | |
Intangibles to total assets | 0.14 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | -0.1 | 0 | 0 | |
Capex to depreciation | 0 | -0.03 | -2.72 | 0 | 0.11 | |
Stock based compensation to revenue | 0.49 | 0.09 | 3.76 | 2.33 | 0 | |
Graham number | 26.59 | 32.8 | 27.5 | 17.39 | 17.82 | |
ROIC | -1.27 | -0.35 | -0.75 | -0.95 | -0.77 | |
Return on tangible assets | -1.35 | -0.44 | -0.75 | -0.78 | -0.58 | |
Graham Net | -9.48 | 8.01 | 7.44 | 2.49 | 3.03 | |
Working capital | 55.07M | 127.85M | 87.15M | 71.21M | 117.3M | |
Tangible asset value | -12.83M | 115.27M | 87.56M | 47.39M | 78.53M | |
Net current asset value | -52.91M | 105.86M | 84.64M | 45.21M | 72.5M | |
Invested capital | 14.99 | 0.2 | 0.03 | 0.57 | 0.52 | |
Average receivables | 1.42M | 1.38M | 377.5K | 273.5K | 36.5K | |
Average payables | 9.95M | 5.77M | 2.09M | 3.6M | 6.04M | |
Average inventory | 1.71M | 1.55M | -50.39M | -50.39M | 0 | |
Days sales outstanding | 52.78 | 0.99 | 91.74 | 4.36 | 0 | |
Days payables outstanding | 1.26K | 20.28 | 4.08K | 15.16K | 42.29K | |
Days of inventory on hand | 402.58 | 0 | -178.55K | 0 | 0 | |
Receivables turnover | 6.92 | 370.36 | 3.98 | 83.74 | 0 | |
Payables turnover | 0.29 | 18 | 0.09 | 0.02 | 0.01 | |
Inventory turnover | 0.91 | 0 | 0 | 0 | 0 | |
ROE | -23.58 | -0.59 | -0.93 | -1.56 | -1.11 | |
Capex per share | 0 | 0 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.15 | 0 | 0 | 0 | 0 | |
Net income per share | -0.99 | -0.77 | -1.37 | -0.75 | -1.02 | |
Operating cash flow per share | -0.98 | -1.21 | -1.12 | -0.62 | -1.11 | |
Free cash flow per share | -0.98 | -1.21 | -1.12 | -0.62 | -1.11 | |
Cash per share | 5.16 | 6.65 | 10.33 | 6.18 | 5.15 | |
Book value per share | 2.78 | 3.24 | 6.92 | 3.89 | 2.93 | |
Tangible book value per share | 2.78 | 3.24 | 6.92 | 3.89 | 2.93 | |
Share holders equity per share | 2.78 | 3.24 | 6.92 | 3.89 | 2.93 | |
Interest debt per share | 1.63 | 2.61 | 2.46 | 1.61 | 1.57 | |
Market cap | 81.8M | 84.29M | 131.93M | 217.8M | 218.22M | |
Enterprise value | 33.93M | 29.96M | -8.66M | 164.85M | 180.94M | |
P/E ratio | -1.22 | -1.64 | -1.36 | -2.72 | -1.99 | |
Price to sales ratio | 31.51 | 0 | 0 | 0 | 0 | |
POCF ratio | -4.92 | -4.15 | -6.63 | -13.13 | -7.35 | |
PFCF ratio | -4.92 | -4.15 | -6.63 | -13.13 | -7.35 | |
P/B Ratio | 1.73 | 1.56 | 1.07 | 2.09 | 2.78 | |
PTB ratio | 1.73 | 1.56 | 1.07 | 2.09 | 2.78 | |
EV to sales | 13.07 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.11 | -2 | 0.37 | -8.73 | -5.81 | |
EV to operating cash flow | -2.04 | -1.48 | 0.44 | -9.94 | -6.1 | |
EV to free cash flow | -2.04 | -1.48 | 0.44 | -9.94 | -6.1 | |
Earnings yield | -0.21 | -0.15 | -0.18 | -0.09 | -0.13 | |
Free cash flow yield | -0.2 | -0.24 | -0.15 | -0.08 | -0.14 | |
Debt to equity | 0.57 | 0.79 | 0.35 | 0.4 | 0.52 | |
Debt to assets | 0.28 | 0.36 | 0.22 | 0.24 | 0.27 | |
Net debt to EBITDA | 2.98 | 3.63 | 6.07 | 2.81 | 1.2 | |
Current ratio | 4.29 | 5.32 | 9.14 | 7.33 | 5.45 | |
Interest coverage | -23.27 | -25.15 | -18.1 | -18.87 | -27.8 | |
Income quality | 0.99 | 1.29 | 0.82 | 0.83 | 1.08 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 4.14 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0.5 | 0 | 0 | 0 | 0 | |
Graham number | 7.86 | 7.49 | 14.6 | 8.09 | 8.2 | |
ROIC | -0.22 | -0.16 | -0.11 | -0.15 | -0.26 | |
Return on tangible assets | -0.18 | -0.11 | -0.13 | -0.11 | -0.18 | |
Graham Net | 2.36 | 2.66 | 6.43 | 3.5 | 2.5 | |
Working capital | 71.21M | 96.53M | 169.18M | 150.67M | 117.3M | |
Tangible asset value | 47.39M | 54.18M | 122.75M | 104.34M | 78.53M | |
Net current asset value | 45.21M | 52.2M | 120.96M | 102.67M | 72.5M | |
Invested capital | 0.57 | 0.79 | 0.35 | 0.4 | 0.52 | |
Average receivables | 52.5K | 46.5K | 32K | 22K | 42K | |
Average payables | 5.13M | 4.9M | 4.73M | 4.84M | 6.15M | |
Average inventory | 0 | -31K | -31K | -21K | -21K | |
Days sales outstanding | 1.07 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 15.21K | 14.71K | 18.63K | 92.12K | 129.31K | |
Days of inventory on hand | 0 | -186 | 0 | -756 | 0 | |
Receivables turnover | 83.74 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.01 | 0.01 | 0 | 0 | 0 | |
Inventory turnover | 0 | -0.48 | 0 | -0.12 | 0 | |
ROE | -0.35 | -0.24 | -0.2 | -0.19 | -0.35 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
VSTM Frequently Asked Questions
What is Verastem, Inc. stock symbol ?
Verastem, Inc. is a US stock , located in Needham of Ma and trading under the symbol VSTM
Is Verastem, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $5. The lowest prediction is $5 and the highest is $5
What is VSTM stock prediction ?
What is Verastem, Inc. stock quote today ?
Verastem, Inc. stock price is $11.86 today.
Is Verastem, Inc. stock public?
Yes, Verastem, Inc. is a publicly traded company.